Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors

Patent metadata

Field	Value
Publication number	US-9873740-B2
Application number	US-201414333375-A
Country	US
Kind code	B2
Filing date	Jul 16, 2014
Priority date	Jul 16, 2013
Publication date	Jan 23, 2018
Grant date	Jan 23, 2018

Abstract

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and an agent that decreases or inhibits TIGIT expression and/or activity and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer or chronic infection.

First claim

What is claimed is:

1. A method for treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of (i) a PD-L1 binding antagonist that inhibits the binding of PD-L1 to PD-1, a PD-1 binding antagonist that inhibits the binding of PD-1 to PD-L1 and/or PD-L2, or a PD-L2 binding antagonist that inhibits the binding of PD-L2 to PD-1 and (ii) an agent that decreases or inhibits TIGIT signaling, wherein the agent is an antagonist of PVR that antagonizes PVR activity in response to TIGIT interaction without impacting PVR-CD96 or PVR-CD226 interaction.

2. A method for treating or delaying progression of a viral infection in an individual comprising administering to the individual an effective amount of (i) a PD-L1 binding antagonist that inhibits the binding of PD-L1 to PD-1, a PD-1 binding antagonist that inhibits the binding of PD-1 to PD-L1 and/or PD-L2, or a PD-L2 binding antagonist that inhibits the binding of PD-L2 to PD-1 and (ii) an agent that decreases or inhibits TIGIT signaling, wherein the agent is an antagonist of PVR that antagonizes PVR activity in response to TIGIT interaction without impacting PVR-CD96 or PVR-CD226 interaction.

3. A method of treating or delaying progression of cancer in an individual comprising administering to the individual an effective amount of (i) a PD-L1 binding antagonist that inhibits the binding of PD-L1 to PD-1, a PD-1 binding antagonist that inhibits the binding of PD-1 to PD-L1 and/or PD-L2, or a PD-L2 binding antagonist that inhibits the binding of PD-L2 to PD-1 and (ii) an agent that increases or stimulates CD226 signaling, wherein the agent is an antagonist of PVR that antagonizes PVR activity in response to TIGIT interaction without impacting PVR-CD96 or PVR-CD226 interaction.

4. A method for treating or delaying progression of a viral infection in an individual comprising administering to the individual an effective amount of (i) a PD-L1 binding antagonist that inhibits the binding of PD-L1 to PD-1, a PD-1 binding antagonist that inhibits the binding of PD-1 to PD-L1 and/or PD-L2, or a PD-L2 binding antagonist that inhibits the binding of PD-L2 to PD-1 and (ii) an agent that increases or stimulates CD226 signaling, wherein the agent is an antagonist of PVR that antagonizes PVR activity in response to TIGIT interaction without impacting PVR-CD96 or PVR-CD226 interaction.

5. A method of increasing, enhancing, or stimulating an immune response or function in an individual comprising administering to the individual an effective amount of (i) a PD-L1 binding antagonist that inhibits the binding of PD-L1 to PD-1, a PD-1 binding antagonist that inhibits the binding of PD-1 to PD-L1 and/or PD-L2, or a PD-L2 binding antagonist that inhibits the binding of PD-L2 to PD-1 and (ii) an agent that increases or stimulates CD226 signaling, wherein the agent is an antagonist of PVR that antagonizes PVR activity in response to TIGIT interaction without impacting PVR-CD96 or PVR-CD226 interaction.

6. The method of any one of claims 1 , 3 , and 5 , further comprising administering at least one chemotherapeutic agent.

7. The method of claim 5 , wherein the individual has cancer.

8. The method of any one of claims 1 , 3 , and 7 , wherein the cancer has elevated levels of T cell infiltration.

9. The method of any one of claims 1 , 2 , 3 , 4 , 5 , and 7 , wherein the PD-L1 binding antagonist is an anti-PD-L1 antibody.

10. The method of claim 9 , wherein the anti-PD-L1 antibody comprises a heavy chain comprising HVR-H1 sequence of GFTFSDSWIH (SEQ ID NO:17), HVR-H2 sequence of AWISPYGGSTYYADSVKG (SEQ ID NO:18), and HVR-H3 sequence of RHWPGGFDY (SEQ ID NO:19); and a light chain comprising HVR-L1 sequence of RASQDVSTAVA (SEQ ID NO:20), HVR-L2 sequence of SASFLYS (SEQ ID NO:21), and HVR-L3 sequence of QQYLYHPAT (SEQ ID NO:22).

11. The method of claim 10 , wherein the anti-PD-L1 antibody comprises a heavy chain variable region comprising the amino acid sequence of EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSA (SEQ ID NO:23), EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTK (SEQ ID NO:40), or EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTI SADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSS (SEQ ID NO:41), and a light chain variable region comprising the amino acid sequence of DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKR (SEQ ID NO:24).

12. The method of any one of claims 1 , 3 , and 7 , wherein the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, renal cell cancer, colorectal cancer, ovarian cancer, breast cancer, pancreatic cancer, gastric carcinoma, bladder cancer, esophageal cancer, mesothelioma, melanoma, head and neck cancer, thyroid cancer, sarcoma, prostate cancer, glioblastoma, cervical cancer, thymic carcinoma, leukemia, lymphomas, myelomas, mycoses fungoides, merkel cell cancer, and other hematologic malignancies.

13. The method of any one of claims 1 , 2 , 3 , 4 , and 5 , wherein the antagonist of PVR is selected from the group consisting of an inhibitory antibody or antigen-binding fragment thereof, an aptamer, an inhibitory nucleic acid, and an inhibitory polypeptide.

Assignees

• Genentech Inc

Inventors

• Grogan Jane
• Johnston Robert J
• Irving Bryan
• Hackney Jason
• Yu Xin
• Eaton Dan
• Bowles Kristin
• Comps-Agrar Laetitia

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P31/12

  Antivirals · CPC title